Spero Therapeutics Inc (SPRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -28,385 | -25,180 | -13,266 | -46,415 | -73,186 |
| Depreciation Amortization | 329 | 221 | 113 | 869 | 740 |
| Accounts payable and accrued liabilities | 486 | 693 | -34 | -484 | 1,483 |
| Other Working Capital | 593 | -10,961 | -2,106 | 22,087 | 7,095 |
| Other Operating Activity | 11,475 | 3,810 | 2,440 | 16,212 | 11,655 |
| Operating Cash Flow | $-15,502 | $-31,417 | $-12,853 | $-7,731 | $-52,213 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | N/A | N/A | 33,807 | 33,807 |
| Investing Cash Flow | $N/A | $N/A | $N/A | $33,807 | $33,807 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | N/A | N/A | 24,932 | 10,753 |
| Other Financing Activity | 220 | 0 | 0 | -54,485 | -54,485 |
| Financing Cash Flow | $220 | $N/A | $N/A | $-29,553 | $-43,732 |
| Beginning Cash Position | 109,107 | 109,107 | 109,107 | 112,584 | 112,584 |
| End Cash Position | 93,825 | 77,690 | 96,254 | 109,107 | 50,446 |
| Net Cash Flow | $-15,282 | $-31,417 | $-12,853 | $-3,477 | $-62,138 |
| Free Cash Flow | |||||
| Operating Cash Flow | -15,502 | -31,417 | -12,853 | -7,731 | -52,213 |
| Free Cash Flow | -15,502 | -31,417 | -12,853 | -7,731 | -52,213 |